Mark Rothera
2016 - PTC Therapeutics
In 2016, Mark Rothera earned a total compensation of $2M as Chief Commercial Officer at PTC Therapeutics, a 30% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $192,173 |
|---|---|
| Option Awards | $1,341,963 |
| Salary | $438,152 |
| Other | $23,532 |
| Total | $1,995,819 |
Rothera received $1.3M in option awards, accounting for 67% of the total pay in 2016.
Rothera also received $192.2K in non-equity incentive plan, $438.2K in salary and $23.5K in other compensation.
Rankings
In 2016, Mark Rothera's compensation ranked 4,890th out of 14,075 executives tracked by ExecPay. In other words, Rothera earned more than 65.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,890 out of 14,075 | 65th |
Division Manufacturing | 1,740 out of 5,488 | 68th |
Major group Chemicals And Allied Products | 545 out of 1,900 | 71st |
Industry group Drugs | 401 out of 1,543 | 74th |
Industry Pharmaceutical Preparations | 319 out of 1,173 | 73rd |
Source: SEC filing on April 27, 2017.
Rothera's colleagues
We found four more compensation records of executives who worked with Mark Rothera at PTC Therapeutics in 2016.